

## ALCOHOLIC CARDIOMYOPATHY: A CASE REPORT

JORDANA DE PAULA MOURA<sup>1</sup>; JORGE TADEU NABUTH<sup>2</sup>; LEONARDO MOURA<sup>3</sup>

1. Cardiology Resident at UniEvangélica - Goiânia, GO, Brazil

2. Professor at UniEvangélica - Goiânia, GO, Brazil

3. Olavo Schermer Hospital - Palmeiras de Goiás, GO, Brazil

### ABSTRACT

**Introduction:** Alcoholic cardiomyopathy is a type of acquired dilated cardiomyopathy associated with excessive and prolonged alcohol consumption. There are two phases: the preclinical phase and the symptomatic phase (characterized by signs and symptoms of heart failure). The diagnosis is often made at a later stage, with significant impairment of overall systolic function. **Objective:** To report the clinical case of a patient with alcoholic cardiomyopathy. **Case Report:** A 62-year-old male patient, hypertensive, with a history of hospitalization for upper gastrointestinal bleeding, presented for consultation to adjust antihypertensive medication. No significant changes were observed in the semiological examination. Upon physical examination, left heart cavity dilation and an ejection fraction of 34% were detected. Following this, a cardiac magnetic resonance imaging was requested, which confirmed the diagnosis of dilated cardiomyopathy, likely of alcoholic etiology, and an implantable cardioverter-defibrillator (ICD) was recommended. **Final considerations:** Dilated cardiomyopathy is a disease with a significant impact on morbidity, mortality, and patients' quality of life, and its early diagnosis is essential for preventing or slowing the progression of the disease. Patient education on the adverse effects associated with excessive alcohol consumption is crucial for preventing the development of this pathology and/or the progression of heart failure.

**Keywords:** Alcohol; Alcoholic cardiomyopathy; Heart failure.

### INTRODUCTION

Alcoholic cardiomyopathy, formerly known as alcoholic heart muscle disease, is a type of acquired dilated cardiomyopathy that occurs in two distinct phases: an initial preclinical phase and a symptomatic phase, characterized by excessive and prolonged alcohol consumption.<sup>1</sup>

During the progression of cardiac dysfunction, certain signs of abnormality can be identified before it becomes clinically evident. Detecting these signs is crucial because, in this preclinical/asymptomatic phase, early cessation of alcohol consumption can reverse left ventricular (LV) dysfunction.<sup>2</sup> In asymptomatic patients, based on the duration of alcohol use, the following echocardiographic findings may be observed: after 5 to 9 years of consumption, an increase in LV volume and prolonged isovolumic relaxation time; after 10 to 15 years, an increase in LV mass and deceleration time; and after 16 to 28 years, an increase in the peak A-wave velocity and a decreased E/A wave peak ratio.<sup>3</sup> Other studies also commonly show echocardiographic findings of diastolic dysfunction in asymptomatic patients.<sup>4</sup>

The exact prevalence of alcoholic cardiomyopathy remains to be determined.<sup>5</sup> However, alcoholic cardiomyopathy accounts for 21 to 36% of non-ischemic dilated cardiomyopathy (DCM) cases in Western societies, and without alcohol abstinence, it has an approximate 4-year mortality rate of 50%.<sup>6</sup> In the United States, alcoholic cardiomyopathy is the most common cause of non-ischemic dilated cardiomyopathy, representing 3.8% of all cardiomyopathies.<sup>7</sup>

In alcoholic cardiomyopathy, two distinct phases are recognized in the disease's natural progression: an initial preclinical/asymptomatic phase, characterized by left ventricular (LV) dilation, with or without diastolic dysfunction, and a second clinical phase, presenting classic symptoms of heart failure (HF), such as dyspnea, orthopnea, edema, nocturia, and tachycardia. HF symptoms may result from initial diastolic dysfunction or later systolic dysfunction. In advanced stages, when the risk of developing atrial fibrillation (AF) increases, there is a possibility of thrombus formation in the dilated atria.<sup>8</sup>

A key factor in identifying alcoholic cardiomyopathy is a history of chronic excessive alcohol consumption, along with a range of cellular, histological, and structural changes in the myocardium that may be present in these individuals.<sup>9</sup>

In clinical practice, echocardiography is the primary imaging test used to monitor cardiac function, while other tests, such as electrocardiography and magnetic resonance imaging, may also be utilized. In patients with alcoholic cardiomyopathy, the echocardiogram may show a dilated left ventricle, with increased diastolic and systolic dimensions and a reduced ejection fraction. Early detection of these echocardiographic signs, which indicate cardiac abnormality, can lead to earlier treatment and, consequently, a better prognosis.<sup>10</sup>

Endomyocardial biopsy remains the gold standard for diagnosing many cardiac conditions, both primary and secondary. However, while there are indeed pathologies such as amyloidosis and cardiac sarcoidosis that can be definitively diagnosed by cardiac biopsy, other etiologies display less specific histopathological features, so their definitive diagnosis is not histological.<sup>11</sup>

In treating individuals with alcoholic cardiomyopathy (ACM), two main objectives should be considered: preventing further damage to the heart muscle by stopping alcohol consumption and reducing cardiac dilation.<sup>12</sup> Total alcohol abstinence is necessary, and additional measures include promoting proper nutritional habits, smoking cessation, and other healthy practices. Thus, ACM treatment follows the standardized heart failure (HF) treatment regimen, including ACE inhibitors, beta-blockers, diuretics, and digitalis, along with anticoagulants when appropriate.<sup>13</sup>

In light of this, the overall objective of this study is to analyze the national and international scientific production indexed in the databases LILACS, SciELO, and PubMed, to report the clinical case of a patient with alcoholic cardiomyopathy.

## CASE REPORT

A 62-year-old male patient from Nova Veneza, GO, attended a private consultation for medication adjustment for hypertension on June 5, 2024.

He had a history of hospitalization 7 years before due to hematemesis associated with abdominal pain. However, there was no history of the use of potentially ulcerogenic medications, gastritis, *H. pylori* infection, peptic ulcer disease, malignancy, angiodysplasia, aortoenteric fistula, or gastroenteric anastomosis. An important factor was his alcohol consumption since his youth.

Upon physical examination, the patient weighed 83 kg; his height was 1.70 m, resulting in a BMI of 28.7 kg/m<sup>2</sup>. Respiratory rate was normal, heart rate was 70 bpm, and blood pressure was 110/80 mmHg. In the cardiovascular examination, the heart rhythm was regular, with normal heart sounds present in two beats, and no murmurs; the abdomen was flat, with present bowel sounds, tympanic, non-tender, and without signs of portal hypertension. No edema was observed in the lower limbs, and the calves were free. He reported alcohol consumption of 200 ml of distilled spirits daily from ages 30 to 50, after which his intake increased to 2 liters of beer per day. He has a

history of systemic arterial hypertension and is taking captopril 25 mg once daily. He denied smoking, illicit drug use, and engaging in physical activity.

Laboratory tests conducted on May 6, 2024, revealed the following results: hemoglobin 13 g/dL, hematocrit 40.3%, leukocytes 11 k/uL (56.2% neutrophils, 1% basophils, 29% lymphocytes, 12.7% monocytes), glucose 85 mg/dL; hemoglobin A1c of 5.7%; creatinine 1.1 mg/dL; potassium 3.6 mEq/L; urinalysis: specific gravity 1.025, proteinuria 15 mg/L, sediment: leukocytes 3,000/mL, erythrocytes 1,000, hyaline casts 0/mL. TSH was 0.7 U/L; free T4 was 6 µg/L; NT-pro BNP was 759 pg/mL; total cholesterol was 148 mg/dL; HDL was 35 mg/dL; LDL was 101 mg/dL; and triglycerides were 62 mg/dL. The serology for Chagas disease was negative.

The transthoracic echocardiogram conducted on May 6, 2024, revealed an aortic diameter of 37 mm, a left atrium measuring 42 mm, a left ventricle diastolic diameter of 62 mm, and a systolic diameter of 53 mm, with a significantly reduced left ventricular ejection fraction of 30%. There were no valvular abnormalities. Thus, a moderately enlarged left atrium was observed, with the left ventricle showing mild eccentric myocardial hypertrophy and significant impairment of systolic function.

The 24-hour Holter monitor conducted on May 6, 2024, revealed a regular rhythm, with a PR interval within normal limits, interventricular conduction disturbance with a QRS complex duration of 170 ms, and the presence of isolated supraventricular ectopic beats. No pauses were observed.

Based on this, the presence of heart failure with reduced ejection fraction (HFrEF) was evidenced. To complement the diagnosis, a cardiac magnetic resonance imaging (MRI) was requested to assess for fibrosis and myocardial viability to elucidate the etiology of the heart failure, and the patient was advised to cease alcohol consumption. Captopril was also discontinued, and the following medications were initiated: Forxiga 10 mg, losartan 50 mg, spironolactone 25 mg, Concardio 1.25 mg, and amiodarone 200 mg.

At the follow-up on June 18, 2024, the MRI revealed a left ventricle with significantly increased dimensions and important global systolic dysfunction, with the presence of septal dyssynchrony, as well as faint linear basal septal mesocardial fibrosis (non-ischemic pattern), which is frequently found in dilated cardiomyopathy. A small late enhancement in the inferior junction was also noted, which is often seen in right chamber overload. Therefore, an implantable cardioverter-defibrillator (ICD) implantation was requested to prevent sudden death in patients with heart failure and reduced ejection fraction of non-ischemic etiology.

## DISCUSSION

According to epidemiological data, alcoholic cardiomyopathy is one of the main non-ischemic etiologies of heart failure in the Western world<sup>14</sup>. The development of alcoholic cardiomyopathy appears to be related to the amount of alcohol consumed daily and the duration of the period of alcohol abuse. Although the exact quantity and duration of abuse are not well defined, a consumption exceeding 80 g/day for at least 5 years is associated with an increased risk of developing cardiomyopathy.<sup>15</sup>

The prevalence of alcoholic cardiomyopathy is higher in men due to the greater prevalence of alcoholism in the male sex<sup>16</sup>, as observed in the above report. However, women reach a higher blood alcohol concentration than men for the same amount of alcohol consumed.<sup>17</sup>

A history of chronic alcohol abuse in the absence of other etiologies of dilated cardiomyopathy suggests a diagnosis of alcoholic cardiomyopathy. The findings on chest radiography are similar to those seen in other causes of cardiomyopathies, such as cardiomegaly, pulmonary congestion, and pleural effusion.<sup>18</sup> The electrocardiogram (ECG) is also non-specific and may show ST segment and T wave changes, low voltage in the presence of significant fibrosis, bundle branch blocks, and cardiac arrhythmias. Biomarkers, such as natriuretic peptides and high-sensitivity troponins, may be elevated and should be interpreted similarly to other etiologies of heart failure. The

echocardiogram can help exclude other causes of heart failure and define the phenotypic pattern of hypertrophy, dilation, diastolic dysfunction, or left ventricular systolic dysfunction, which may precede the onset of symptoms. Cardiac magnetic resonance imaging may reveal areas of late enhancement, indicating myocardial fibrosis.<sup>19</sup> Abstinence from alcohol is fundamental in the treatment of alcoholic cardiomyopathy. Heart failure syndrome should be managed similarly to other etiologies. Therefore, beta-blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, spironolactone, and diuretics for cases of congestion are indicated.<sup>20</sup> In certain groups with heart failure, such as our patient, it has been shown that an implantable cardioverter-defibrillator (ICD) can prolong patient survival. It may be indicated to prevent sudden death in patients with heart failure and reduced ejection fraction (HFrEF) who have left ventricular dysfunction due to anterior myocardial infarction (MI) with an ejection fraction (EF) of 30-40% or less; those with sustained ventricular tachycardia (VT) that is hemodynamically unstable; those with cardiac arrest due to VT/fibrillation ventricular (VF) from a non-reversible cause and EF  $\leq$  35%; and those with spontaneous VT with hemodynamic compromise or syncope, also from a non-reversible cause and EF  $\leq$  35%.<sup>21</sup> Important to note that an ICD should not be indicated for patients with a life expectancy of less than one year.<sup>22</sup>

## FINAL CONSIDERATIONS

Alcoholic dilated cardiomyopathy is a myocardial dysfunction that causes heart failure, characterized by predominant ventricular dilation and systolic dysfunction. The symptoms include dyspnea, fatigue, and peripheral edema. The diagnosis is clinical and is supplemented by tests such as transthoracic echocardiography and cardiac MRI. The treatment is directed at the cause of heart failure (HF). Among the pharmacological therapies, we can mention angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, aldosterone receptor blockers, angiotensin II receptor blockers, neprilysin inhibitors, sodium-glucose cotransporter 2 (SGLT2) inhibitors, hydralazine/nitrates, as well as diuretics. Furthermore, when ventricular dysfunction is significant, cardiac resynchronization therapy and implantable cardioverter-defibrillator (ICD) are indicated.

## REFERENCES

1. Dundung A, Kumar A, Guria RT, Preetam M, Tara RK, Kumar B, Saba MK. Clinical profile and prognostic factors of alcoholic cardiomyopathy in tribal and non-tribal population. *Open Heart* [Internet]. 2020 Nov;7(2):e001335. doi: 10.1136/openhrt-2020-001335. Erratum in: *Open Heart* [Internet]. 2020 Dec [Cited 2024 Oct 21];7(2):e001335corr1. Available from: <https://openheart.bmj.com/content/7/2/e001335corr1> doi: 10.1136/openhrt-2020-001335corr1
2. Chiva-Blanch G, Badimon L. Benefits and risks of moderate alcohol consumption on cardiovascular disease: current findings and controversies. *Nutrients* [Internet]. 2019 Dec 30 [Cited 2024 Oct 21];12(1):108. Available from: <https://www.mdpi.com/2072-6643/12/1/108> doi: 10.3390/nu12010108
3. Corrêa VP, de Oliveira CM, Vieira DSR, Garcia CAS Jr, Schneider IJC. Socioemotional factors and cardiovascular risk: what is the relationship in Brazilian older adults? *Innov Aging* [Internet]. 2023 Jul 26 [Cited 2024 Oct 21];7(7):igad078. Available from: <https://academic.oup.com/innovateage/article/7/7/igad078/7231384> doi: 10.1093/geroni/igad078
4. de Freitas MG, Silva END. Direct and indirect costs attributed to alcohol consumption in Brazil, 2010 to 2018. *PLoS One* [Internet]. 2022 Oct 25 [Cited 2024 Oct 21];17(10):e0270115. Available from: <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0270115> doi: 10.1371/journal.pone.0270115
5. Zhang J, Liu H, Bu X, Lu Q, Cheng L, Ma A, Wang T. The burden of alcoholic cardiomyopathy in China and different regions around the world. *J Glob Health* [Internet]. 2022 Jul 30 [Cited 2024 Oct 21];12:04041. Available from: <https://jogh.org/2022/jogh-12-04041> doi: 10.7189/jogh.12.04041

6. Ribeiro GJS, Moriguchi EH, Pinto AA. Clustering of cardiovascular risk factors and heart failure in older adults from the Brazilian far north. *Healthcare (Basel)* [Internet]. 2024 May 6 [Cited 2024 Oct 21];12(9):951. Available from: <https://www.mdpi.com/2227-9032/12/9/951> doi: 10.3390/healthcare12090951
7. Miguez FGG, Oliveira G, Correa MM, Oliveira ERA. Study of cardiovascular risks in adolescents (ERICA): alcohol consumption and associated factors. *Rev Bras Epidemiol* [Internet]. 2023 May 8 [Cited 2024 Oct 21];26:e230025. Available from: <https://www.scielo.br/j/rbepid/a/wjWtYGTGfWjDqT5rG4Xwbj/?lang=en> doi: 10.1590/1980-549720230025
8. Barbosa JSP, Pereira LC, Salgado FXC, da Silva RM, Karnikowski MGO. An assessment of mortality among elderly Brazilians from alcohol abuse diseases: a longitudinal study from 1996 to 2019. *Int J Environ Res Public Health* [Internet]. 2022 Oct 18 [Cited 2024 Oct 21];19(20):13467. Available from: <https://www.mdpi.com/1660-4601/19/20/13467> doi: 10.3390/ijerph192013467
9. Rohde LE, Beck-da-Silva L. Alcohol and the heart: the good, the bad and the worse in heart failure. *Heart* [Internet]. 2018 Oct [Cited 2024 Oct 21];104(20):1641-2. Available from: <https://heart.bmj.com/content/104/20/1641> doi: 10.1136/heartjnl-2017-312924
10. Rasoul D, Ajay A, Abdullah A, Mathew J, Lee Wei En B, Mashida K, Sankaranarayanan R. Alcohol and heart failure. *Eur Cardiol* [Internet]. 2023 Dec 26 [Cited 2024 Oct 21];18:e65. Available from: <https://www.eurjournal.com/articles/alcohol-and-heart-failure> doi: 10.15420/ecr.2023.12
11. Lyu X, Miskovsky J. Detecting concealing heart failure in a young alcohol-related liver failure patient using the most basic pathophysiological principle. *Cureus* [Internet]. 2022 Mar 28 [Cited 2024 Oct 21];14(3):e23570. Available from: <https://www.cureus.com/articles/90981-detecting-concealing-heart-failure-in-a-young-alcohol-related-liver-failure-patient-using-the-most-basic-pathophysiological-principle#!> doi: 10.7759/cureus.23570
12. G-CHF Investigators; Joseph P, Roy A, Lonn E, Störk S, Floras J, Mielniczuk L, Rouleau JL, Zhu J, Dzudie A, Balasubramanian K, Karaye K, AlHabib KF, Gómez-Mesa JE, Branch KR, Makubi A, Budaj A, Avezum A, Wittlinger T, Ertl G, Mondo C, Pogossova N, Maggioni AP, Orlandini A, Parkhomenko A, ElSayed A, López-Jaramillo P, Grinvalds A, Temizhan A, Hage C, Lund LH, Kazmi K, Lanas F, Sharma SK, Fox K, McMurray JJV, Leong D, Dokainish H, Khetan A, Yonga G, Kragholm K, Wagdy Shaker K, Mwita JC, Al-Mulla AA, Alla F, Damasceno A, Silva-Cardoso J, Dans AL, Sliwa K, O'Donnell M, Bazargani N, Bayés-Genís A, McCready T, Probstfield J, Yusuf S. Global variations in heart failure etiology, management, and outcomes. *JAMA* [Internet]. 2023 May 16;329(19):1650-1661. doi: 10.1001/jama.2023.5942. Erratum in: *JAMA* [Internet]. 2023 Sep 5 [Cited 2024 Oct 21];330(9):880. Available from: <https://jamanetwork.com/journals/jama/fullarticle/2809029> doi: 10.1001/jama.2023.12973
13. Day E, Rudd JHF. Alcohol use disorders and the heart. *Addiction* [Internet]. 2019 Sep [Cited 2024 Oct 21];114(9):1670-8. Available from: <https://onlinelibrary.wiley.com/doi/10.1111/add.14703> doi: 10.1111/add.14703
14. Maisch B. Alcoholic cardiomyopathy : The result of dosage and individual predisposition. *Herz* [Internet]. 2016 Sep [Cited 2024 Oct 21];41(6):484-93. Available from: <https://link.springer.com/article/10.1007/s00059-016-4469-6> doi: 10.1007/s00059-016-4469-6
15. Fernández-Solà J. The effects of ethanol on the heart: alcoholic cardiomyopathy. *Nutrients* [Internet]. 2020 Feb 22 [Cited 2024 Oct 21];12(2):572. Available from: <https://www.mdpi.com/2072-6643/12/2/572> doi: 10.3390/nu12020572
16. Mirijello A, Tarli C, Vassallo GA, Sestito L, Antonelli M, d'Angelo C, Ferrulli A, De Cosmo S, Gasbarrini A, Addolorato G. Alcoholic cardiomyopathy: what is known and what is not known. *Eur J Intern Med* [Internet]. 2017 Sep [Cited 2024 Oct 21];43:1-5. Available from: [https://www.ejinme.com/article/S0953-6205\(17\)30258-3/abstract](https://www.ejinme.com/article/S0953-6205(17)30258-3/abstract) doi: 10.1016/j.ejim.2017.06.014
17. Ihekire NL, Okobi OE, Adedoye EA, Akahara PF, Onyekwere AO, Afrifa-Yamoah J, Akinyemi FB. Heartache in a bottle: understanding alcoholic cardiomyopathy. *Cureus* [Internet]. 2023 Aug 3 [Cited 2024 Oct 21];15(8):e42886. Available from: <https://www.cureus.com/articles/166801-heartache-in-a-bottle-understanding-alcoholic-cardiomyopathy#!> doi: 10.7759/cureus.42886
18. Domínguez F, Adler E, García-Pavía P. Alcoholic cardiomyopathy: an update. *Eur Heart J* [Internet]. 2024 Jul 9 [Cited 2024 Oct 21];45(26):2294-305. Available from: <https://academic.oup.com/eurheartj/article/45/26/2294/7689556> doi: 10.1093/eurheartj/ehae362
19. Andersson C, Schou M, Gustafsson F, Torp-Pedersen C. Alcohol intake in patients with cardiomyopathy and heart failure: consensus and controversy. *Circ Heart Fail* [Internet]. 2022 Aug [Cited 2024 Oct 21];15(8):e009459. Available from: <https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.121.009459> doi: 10.1161/CIRCHEARTFAILURE.121.009459



20. Shaaban A, Gangwani MK, Pendela VS, Vindhya MR. Alcoholic cardiomyopathy. 2023 Aug 8 [Cited 2024 Oct 21]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK513322/>

21. Køber L, Thune JJ, Nielsen JC, Haarbø J, Videbæk L, Korup E, Jensen G, Hildebrandt P, Steffensen FH, Bruun NE, Eiskjær H, Brandes A, Thøgersen AM, Gustafsson F, Egstrup K, Videbæk R, Hassager C, Svendsen JH, Høfsten DE, Torp-Pedersen C, Pehrson S; DANISH Investigators. Defibrillator implantation in patients with nonischemic systolic heart failure. *N Engl J Med* [Internet]. 2016 Sep 29 [Cited 2024 Oct 21];375(13):1221-30. Available from: <https://www.nejm.org/doi/10.1056/NEJMoa1608029> doi: 10.1056/NEJMoa1608029

22. Elming MB, Jensen DH, Winsløw UC, Risum N, Butt JH, Yafasova A, Haarbø J, Philbert BT, Svendsen JH, Pehrson S, Køber L, Thune JJ. Right ventricular free wall strain and effect of defibrillator implantation in patients with nonischemic systolic heart failure. *J Card Fail* [Internet]. 2023 Jun [Cited 2024 Oct 21];29(6):883-892. Available from: [https://onlinejcf.com/article/S1071-9164\(23\)00013-1/abstract](https://onlinejcf.com/article/S1071-9164(23)00013-1/abstract) doi: 10.1016/j.cardfail.2022.12.018

JORDANA DE PAULA MOURA - <http://lattes.cnpq.br/6355488699640230> - <https://orcid.org/0009-0000-4245-1457>

JORGE TADEU NABUTH - <http://lattes.cnpq.br/6637431019843256> - <https://orcid.org/0009-0000-2860-3581>

LEONARDO MOURA - <http://lattes.cnpq.br/6981984245986030> - <https://orcid.org/0009-0001-3972-3965>

### MAILING ADDRESS:

JORDANA DE PAULA MOURA

Rua Luiz Gonzaga Rodrigues, 672, Palmeiras de Goiás - GO, Brazil.

E-mail: [jordana\\_paula17@hotmail.com](mailto:jordana_paula17@hotmail.com)

Revisão Bibliotecária - Romulo Arantes

Revisão Ortográfica: Dario Alvares

Recebido: 18/10/24. Aceito: 06/11/24. Publicado em: 07/11/24.